EPISODE · Jan 13, 2024 · 27 MIN
Ep. 210 - J.P. Morgan Healthcare Conference Wrap
from BioCentury This Week · host BioCentury
Cautious optimism was the theme during a J.P. Morgan Healthcare Conference week that featured patchy skies, large-but-not-mega deals and a surfeit of sideline summits around San Francisco’s Union Square. BioCentury’s editorial team discusses the week’s M&A deals, including J&J's $2 billion takeout of ADC company Ambrx, and Merck & Co. acquiring T cell engager biotech Harpoon for nearly $700 million; takeaways from the Sachs Neuroscience Innovation Forum and other adjacent forums; and investor sentiment heading into the New Year.Music for the 24th Bio€quity Europe teaser produced by:Thomas de Paula Eby, Andreas Unge, Epidemic Sound via Getty ImagesReach us by sending a text
Embed this episode
What this episode covers
Cautious optimism was the theme during a J.P. Morgan Healthcare Conference week that featured patchy skies, large-but-not-mega deals and a surfeit of sideline summits around San Francisco’s Union Square. BioCentury’s editorial team discusses the week’s M&A deals, including J&J's $2 billion takeout of ADC company Ambrx, and Merck & Co. acquiring T cell engager biotech Harpoon for nearly $700 million; takeaways from the Sachs Neuroscience Innovation Forum and other adjacent forums; ...
NOW PLAYING
Ep. 210 - J.P. Morgan Healthcare Conference Wrap
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.